Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Susan N. Thomas, Haydn T. Kissick, Brian S. Robinson, Mohammad Y. Zaidi, Rohan K. Dhamsania, Gregory B. Lesinski, Alan B. Frey, Shuhua Wang, Sanjeev Gumber, Michael B. Ware, Jingru Zhu, Yuan Liu, Maria Cardenas, Passang Tenzin, Gaurav N. Joshi, Anish Sen-Majumdar, Shanmuganathan Chandrakasan, Sruthi Ravindranathan, Bassel F. El-Rayes, Jian-Ming Li, Edmund K. Waller
Publikováno v:
Cancer Research. 81:PO-072
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to immune checkpoint therapy largely due to a paucity of T cells within the tumor microenvironment (TME) and abundant immunosuppressive signaling pathways. In this study we show that human PDAC
Autor:
Anne M. Noonan, Leslie Cope, Paul R. Kunk, S. Lindsey Davis, Jill Lacy, Andrew Poklepovic, Lipika Goyal, Autumn McRee, Edward J. Kim, Mark Yarchoan, Daneng Li, Amanda Ruggieri, Aiwu R. He, Helen Chen, Nilo Azad, Stephanie Xavier, Qingfeng Zhu, Robert A. Anders, Laura W. Goff, Ghassan K. Abou-Alfa, Andrea Wang-Gillam, Gregory B. Lesinski, Kristen Spencer, Anuj K. Patel, Elad Sharon
Publikováno v:
Cancer Research. 80:CT043-CT043
Background: BTCs are aggressive cancers with a poor prognosis. In preclinical models, MEK inhibition modulates the tumor immune microenvironment and enhances responses to programmed death-ligand 1 (PD-L1) inhibition. We report a randomized, open-labe
Autor:
Luis I. Ruffolo, Maurice Zauderer, Brian Olson, Gregory B. Lesinski, Alexander C. Chacon, Mary A. Georger, Brian A. Belt, Elizabeth E. Evans, David C. Linehan, Crystal Mallow, Katherine M. Jackson, Paul R. Burchard, Rachel Jewell, Peter A. Prieto, Christina Wu, Terrence L. Fisher, Nicholas A. Ullman, Alexa Melucci
Publikováno v:
Cancer Research. 79:B48-B48
Background: Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality, with dismal 5-year prognosis of 8%, in part due to poor response to available therapies. Thus, new systemic cancer control therapies are in dire nee
Autor:
Lauren Dennison, Matthew R. Farren, Gregory B. Lesinski, Amanda Ruggieri, Bassel El-Reyes, Mark Yarchoan, Nilofer S. Azad
Publikováno v:
Cancer Research. 79:3971-3971
Cholangiocarcinoma (CC) is a rare but aggressive cancer of the bile ducts with a five-year survival rate of only 2% in patients with metastatic disease. MAP kinase signaling is important in the pathogenesis of CC and serves as a key regulator of cell
Autor:
Matthew R. Farren, Bassel F. El-Rayes, Alyssa M. Krasinskas, Juan M. Sarmiento, Walid L. Shaib, Layal Sayegh, Gregory B. Lesinski, David A. Kooby, Olatunji B. Alese, Mohammad Y. Zaidi, Shishir K. Maithel
Publikováno v:
Cancer Research. 79:3967-3967
Pancreatic ductal adenocarcinoma (PDAC) has dismal five-year survival ( Citation Format: Matthew R. Farren, Walid Shaib, Mohammad Zaidi, Layal Sayegh, David Kooby, Shishir Maithel, Alyssa Krasinskas, Olatunji Alese, Juan Sarmiento, Bassel El-Rayes, G
Autor:
Bassel F. El-Rayes, Edmund K. Waller, Sruthi Ravindranathan, Gregory B. Lesinski, Mohammad Y. Zaidi, Shuhua Wang, Yiwen Li
Publikováno v:
Cancer Research. 79:1205-1205
Background: Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer related death in the U.S., outranking breast and colorectal cancer by 2030. Being completely refractory to checkpoint therapies, management
Autor:
Gregory B. Lesinski, Ganji Purnachandra Nagaraju, Matthew R. Farren, Batoul Farran, Bassel F. El-Rayes, Sneha Govardhanagiri, Shipra Reddy Bethi
Publikováno v:
Cancer Research. 79:354-354
Background: The transcription factor signal transducer and activator of transcription 3 (STAT-3) is constitutively activated in pancreatic ductal adenocarcinoma (PDAC) and signaling via this pathway regulates a diverse set of cellular processes inclu
Autor:
Brian Olson, Michael C. Lowe, Maurice Zauderer, Desa Rae Pastore, Crystal Mallow, Conor E. Steuer, John E. Leonard, Ernest S. Smith, Elizabeth E. Evans, Gregory B. Lesinski, Nabil F. Saba, Christina Wu, Ragini R. Kudchadkar, Terrence L. Fisher
Publikováno v:
Cancer Research. 79:CT016-CT016
Interrogation of the tumor microenvironment (TME) is crucial to provide insight into biological activity, resistance mechanisms and implementation of rational combination immunotherapies. Semaphorin 4D (SEMA4D, CD100) has broad immunomodulatory effec
Autor:
Bassel F. El-Rayes, Shipra Reddy Bethi, Ganji Purnachandra Nagaraju, Gregory B. Lesinski, Rajitha Balney, Sneha Govardhanagiri
Publikováno v:
Cancer Research. 79:205-205
Background: Chemoradiotherapy is a standard treatment modality for early stage rectal cancer (CRC). The pathologic complete response rate after chemoradiation in CRC remains low at 15%. Given the potential for BBI608 to elicit effects on multiple onc
Autor:
Conor E. Steuer, Elizabeth E. Evans, Gregory B. Lesinski, Antoni Ribas, Maria Scrivens, Emily Greengard, Alan Howell, Brian Olson, Paul E. Clavijo, Ernest S. Smith, Siwen Hu-Lieskovan, Terrence L. Fisher, Clint T. Allen, Leslie Balch, Sebold Torno, Christina Wu, Christine Reilly, Maurice Zauderer, Nabil F. Saba, Crystal Mallow, Desa Rae Pastore, John E. Leonard, Holm Bussler
Publikováno v:
Cancer Research. 79:1545-1545
Anti-semaphorin 4D (SEMA4D, CD100) blocking antibody promotes immune infiltration, reduces immunosuppressive myeloid cells, and enhances T cell activity and tumor growth inhibition in combination with various immunotherapies in preclinical animal mod